{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:02Z","timestamp":1792114142605,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40273-020-00912-8","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T21:02:14Z","timestamp":1588539734000},"page":"715-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Economic Costs of Myasthenia Gravis: A Systematic Review"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-7151","authenticated-orcid":false,"given":"Erik","family":"Landfeldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Pogoryelova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sejersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Zethraeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Breiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"Lochm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"912_CR1","doi-asserted-by":"publisher","unstructured":"Koneczny I, Herbst R (2019) Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. https:\/\/doi.org\/10.3390\/cells8070671.","DOI":"10.3390\/cells8070671"},{"issue":"3","key":"912_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: association of British Neurologists\u2019 management guidelines. Pract Neurol. 2015;15(3):199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126.","journal-title":"Pract Neurol"},{"issue":"4","key":"912_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/cnd.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromusc Dis. 2014;15(4):167\u201378. https:\/\/doi.org\/10.1097\/cnd.0000000000000034.","journal-title":"J Clin Neuromusc Dis"},{"key":"912_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14195","author":"XJ Cai","year":"2019","unstructured":"Cai XJ, Li ZW, Xi JY, Song HZ, Liu J, Zhu WH, Guo Y, Jiao Z. Myasthenia gravis and specific immunotherapy: monoclonal antibodies. Ann N Y Acad Sci. 2019. https:\/\/doi.org\/10.1111\/nyas.14195.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"912_CR5","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"issue":"1","key":"912_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40258-018-0418-2","volume":"17","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Zethraeus N, Lindgren P. Standardized questionnaire for the measurement, valuation, and estimation of costs of informal care based on the opportunity cost and proxy good method. Appl Health Econ Health Policy. 2019;17(1):15\u201324. https:\/\/doi.org\/10.1007\/s40258-018-0418-2.","journal-title":"Appl Health Econ Health Policy"},{"key":"912_CR7","unstructured":"The World Bank. https:\/\/www.worldbank.org\/. Accessed 13 Sep 2019."},{"key":"912_CR8","unstructured":"Wells G, Shea B, O\u2019Connell J, Robertson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 5 Jan 2019."},{"issue":"2","key":"912_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1590\/s0124-00642012000200007","volume":"14","author":"LA Chicaiza-Becerra","year":"2012","unstructured":"Chicaiza-Becerra LA, Garcia-Molina M, Gamboa O, Castaneda-Orjuela C. The cost-effectiveness of open or thoracoscopic thymectomy compared to medical treatment in managing myasthenia gravis without thymomas. Revista de salud publica (Bogota, Colombia). 2012;14(2):260\u201370. https:\/\/doi.org\/10.1590\/s0124-00642012000200007.","journal-title":"Revista de salud publica (Bogota, Colombia)"},{"issue":"6","key":"912_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/mus.24960","volume":"53","author":"JC Furlan","year":"2016","unstructured":"Furlan JC, Barth D, Barnett C, Bril V. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve. 2016;53(6):872\u20136. https:\/\/doi.org\/10.1002\/mus.24960.","journal-title":"Muscle Nerve"},{"key":"912_CR11","doi-asserted-by":"publisher","unstructured":"Guptill JT, Marano A, Krueger A, Sanders DB (2011) Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve. 44 (6):907\u2013911. https:\/\/doi.org\/10.1002\/mus.22212.","DOI":"10.1002\/mus.22212"},{"key":"912_CR12","doi-asserted-by":"publisher","unstructured":"Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB (2012) Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve 45(3):363\u2013366. https:\/\/doi.org\/10.1002\/mus.22327.","DOI":"10.1002\/mus.22327"},{"issue":"2","key":"912_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","volume":"13","author":"C Heatwole","year":"2011","unstructured":"Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromusc Dis. 2011;13(2):85\u201394. https:\/\/doi.org\/10.1097\/CND.0b013e31822c34dd.","journal-title":"J Clin Neuromusc Dis"},{"issue":"1","key":"912_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","volume":"35","author":"CH Lai","year":"2010","unstructured":"Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology. 2010;35(1):66\u201371. https:\/\/doi.org\/10.1159\/000311012.","journal-title":"Neuroepidemiology"},{"issue":"6","key":"912_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68(6):797\u2013805. https:\/\/doi.org\/10.1002\/ana.22139.","journal-title":"Ann Neurol"},{"key":"912_CR16","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0000000000004239","author":"H Mouri","year":"2019","unstructured":"Mouri H, Jo T, Matsui H, Fushimi K, Yasunaga H. Effect of sugammadex on postoperative myasthenic crisis in myasthenia gravis patients: propensity score analysis of a Japanese nationwide database. Anesth Analg. 2019. https:\/\/doi.org\/10.1213\/ane.0000000000004239.","journal-title":"Anesth Analg"},{"issue":"4","key":"912_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cen3.12411","volume":"8","author":"M Ogino","year":"2017","unstructured":"Ogino M, Okamoto S, Ohta H, Sakamoto M, Nakamura Y, Iwasaki K, Yoshida M, Hiroi S, Kawachi I. Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database. Clin Exp Neuroimmunol. 2017;8(4):318\u201326. https:\/\/doi.org\/10.1111\/cen3.12411.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"6","key":"912_CR18","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mus.25624","volume":"56","author":"JO Omorodion","year":"2017","unstructured":"Omorodion JO, Pines JM, Kaminski HJ. Inpatient cost analysis for treatment of myasthenia gravis. Muscle Nerve. 2017;56(6):1114\u20138. https:\/\/doi.org\/10.1002\/mus.25624.","journal-title":"Muscle Nerve"},{"issue":"1","key":"912_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","volume":"257","author":"K Schepelmann","year":"2010","unstructured":"Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schroder R, Heuss D, Vielhaber S, Mylius V, Kiefer R, Schrank B, Oertel WH, Dodel R. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(1):15\u201323. https:\/\/doi.org\/10.1007\/s00415-009-5256-6.","journal-title":"J Neurol"},{"key":"912_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","volume":"38","author":"KK Sonkar","year":"2017","unstructured":"Sonkar KK, Bhoi SK, Dubey D, Kalita J, Misra UK. Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India. J Clini Neurosci. 2017;38:114\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2016.11.003.","journal-title":"J Clini Neurosci"},{"issue":"3","key":"912_CR21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.59566\/IJBS.2009.5209","volume":"5","author":"N Souayah","year":"2009","unstructured":"Souayah N, Nasar A, Suri MF, Kirmani JF, Ezzeddine MA, Qureshi AI. Trends in outcomes and hospitalization charges among mechanically ventilated patients with myasthenia gravis in the United States. Int J Biomed Sci IJBS. 2009;5(3):209\u201314.","journal-title":"Int J Biomed Sci IJBS"},{"issue":"4","key":"912_CR22","first-page":"286","volume":"19","author":"S Tiamkao","year":"2014","unstructured":"Tiamkao S, Pranboon S, Thepsuthammarat K, Sawanyawisuth K. Prevalence of factors associated with poor outcomes of hospitalized myasthenia gravis patients in Thailand. Neurosciences (Riyadh, Saudi Arabia). 2014;19(4):286\u201390.","journal-title":"Neurosciences (Riyadh, Saudi Arabia)"},{"key":"912_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijcard.2019.09.054","volume":"299","author":"R Desai","year":"2020","unstructured":"Desai R, Abbas SA, Fong HK, Lodhi MU, Doshi R, Savani S, Gangani K, Sachdeva R, Kumar G. Burden and impact of takotsubo syndrome in myasthenic crisis: a national inpatient perspective on the under-recognized but potentially fatal association. Int J Cardiol. 2020;299:63\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2019.09.054.","journal-title":"Int J Cardiol"},{"issue":"3","key":"912_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaad.2019.07.029","volume":"82","author":"S Narla","year":"2020","unstructured":"Narla S, Silverberg JI. Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. J Am Acad Dermatol. 2020;82(3):586\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.029.","journal-title":"J Am Acad Dermatol"},{"key":"912_CR25","unstructured":"Organisation for Economic Co-operation and Development. OECD.Stat Extracts. Available at: http:\/\/stats.oecd.org. Accessed June 2019."},{"issue":"6","key":"912_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/wnl.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, Lochmuller H, Bushby K. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336. https:\/\/doi.org\/10.1212\/wnl.0000000000000669.","journal-title":"Neurology"},{"issue":"3","key":"912_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s41669-018-0107-y","volume":"3","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E. Extending life in Duchenne muscular dystrophy: implications for appraisals of cost-effectiveness. PharmacoEconom Open. 2019;3(3):279\u201380. https:\/\/doi.org\/10.1007\/s41669-018-0107-y.","journal-title":"PharmacoEconom Open"},{"issue":"3","key":"912_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/ene.13836","volume":"26","author":"C Barnett","year":"2019","unstructured":"Barnett C, Bril V, Bayoumi AM. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. Eur J Neurol. 2019;26(3):452\u20139. https:\/\/doi.org\/10.1111\/ene.13836.","journal-title":"Eur J Neurol"},{"key":"912_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1750-1172-9-62","volume":"9","author":"E Picavet","year":"2014","unstructured":"Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9:62. https:\/\/doi.org\/10.1186\/1750-1172-9-62.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"912_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1478-7547-1-8","volume":"1","author":"R Hutubessy","year":"2003","unstructured":"Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effect Resour Alloc C\/E. 2003;1(1):8. https:\/\/doi.org\/10.1186\/1478-7547-1-8.","journal-title":"Cost Effect Resour Alloc C\/E"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-020-00912-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T11:37:16Z","timestamp":1696073836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-020-00912-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1007\/s40273-020-00912-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"4 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Landfeldt is an employee of ICON plc (Stockholm, Sweden), outside the submitted work. Dr. Pogoryelova is an employee of Absolute Antibody (Red Car, UK), outside the submitted work. Professor Sejersen, Professor Zethraeus, Dr. Breiner, and Professor Lochm\u00fcller declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}